On Aug. 15, 2022, the U.S. Department of Health and Human Services announced that was making up to 442,000 doses of the JYNNEOS vaccine available for states and jurisdictions to order under an accelerated Phase 3 of the National Vaccine Strategy (NVS) to combat the current mpox outbreak.

Under the U.S. Food and Drug Administration (FDA) EUA for JYNNEOS, the vaccine may be injected intradermally (in the upper skin layer) for individuals 18 years of age and older who are determined to be at high risk for mpox infection – a change that increases doses by up to five-fold.

The EUA for the JYNNEOS vaccine allows health care providers to inject the vaccine intradermally for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection. A full intradermal dose requires only 0.1mL of vaccine to elicit similar immunogenicity obtained with a 0.5mL subcutaneous dose without compromising the level of immune response achieved or the safety of the vaccine, which means that up to five people can now receive a full dose using just a single vial of vaccine.